Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-Current Assets (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Non-Current Assets data on record, last reported at $279.5 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 21.16% year-over-year to $279.5 million; the TTM value through Dec 2025 reached $1.0 billion, up 33.5%, while the annual FY2025 figure was $279.5 million, 21.16% up from the prior year.
  • Non-Current Assets reached $279.5 million in Q4 2025 per RVMD's latest filing, up from $274.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $279.5 million in Q4 2025 and bottomed at $111.4 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $177.4 million, with a median of $155.8 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: fell 0.65% in 2021, then soared 49.26% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $148.2 million in 2021, then grew by 2.38% to $151.7 million in 2022, then increased by 20.22% to $182.4 million in 2023, then grew by 26.45% to $230.7 million in 2024, then rose by 21.16% to $279.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $279.5 million in Q4 2025, $274.4 million in Q3 2025, and $253.1 million in Q2 2025.